The rapid expansion of glucagon-like peptide-1 receptor agonists (GLP-1s) into non-diabetic weight-loss markets has shifted significant health risk from regulated medical systems onto individual consumers, particularly young women. Originally approved for diabetes treatment, medications such as Ozempic, Wegovy, and Mounjaro have become some of the most sought-after drugs in the United States. Their popularity has been driven not only by clinical effectiveness but also by algorithm-driven marketing, social media normalization, and intensified societal pressures surrounding thinness. High prices, inconsistent insurance coverage, and nationwide shortages have simultaneously fueled demand for compounded and non-FDA-approved GLP-1 products, expanding consumer exposure to regulatory gray areas and potential public health risks.

This research examines the societal impacts of the rise in GLP-1 medications for weight loss and asks how these drugs can be marketed and distributed to prioritize patient safety. This study conducts a structured literature-based analysis of regulatory documents, peer-reviewed scientific studies, investigative journalism, public health reports, and federal data published after 2017. Sources were analyzed comparatively to identify recurring themes related to marketing practices, safety, regulatory oversight, and consumer access. 

The findings are organized into a mapped framework of challenges associated with the weight-loss GLP-1 market, including regulatory gaps in compounding practices, risks of misleading advertising, inequitable access, and shifting responsibility for risk onto consumers. This analysis then pairs documented challenges with targeted policy and regulatory interventions. By evaluating how commercial incentives intersect with public health regulation, this research proposes strategies to strengthen oversight, protect consumers, and mitigate long-term societal harm.